IP Library › Granted Patent US 8,715,736
Granted Patent B2
US 8,715,736 · App. 12/433,344 · Granted May 6, 2014

Nanoparticle formulations for skin delivery

Inventors: Mandip Singh Sachdeva (Tallahassee, FL); Ram Patlolla (Tallahassee, FL)
Assignee: Florida Agricultural and Mechanical University
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,715,736
App. No.
12/433,344
Granted
May 6, 2014
Kind
B2
Abstract

Methods and formulations for treating a condition of the skin by delivering therapeutic formulations to the skin that translocates active substances across the stratum corneum barrier to a targeted skin tissue. The methods and formulations comprise active substances encapsulated within surface modified nanostructured lipid carrier nanoparticles.

Claims (15)

1. A formulation for topical application to a selected target skin tissue in the skin of a subject,

wherein said formulation comprises nanostructured lipid carrier nanoparticles encapsulating an active substance,

wherein the surface of the nanoparticles is modified with a cell penetrating peptide, and

wherein the nanoparticles comprise a blend of solid lipids and liquid lipids,

wherein the blend is solid at body temperature, and

wherein the formulation releases the active substance in a controlled manner upon application to the skin so that it penetrates the skin and is delivered to the epidermis to a depth of from about 80 to about 120 microns.

2. The formulation of claim 1 , wherein the solid lipids are comprised of oil-based or lipidic medium carriers and the liquid lipids are comprised of an organic phase.

3. The formulation of claim 1 , wherein the active substance is an anti-inflammatory agent.

4. The formulation of claim 1 , wherein the active substance is suitable for the treatment of a disease or condition which is localized, or at least partially localized to the skin.

5. The formulation of claim 1 , wherein the disease or condition is selected from the group consisting of psoriasis, irritant contact dermatitis, atopic dermatitis, contact dermatitis, inflammation, eczema, infections including bacterial and fungal infections, acne, rheumatoid arthritis and skin cancer.

6. The formulation of claim 1 , wherein the solid lipids are selected from the group consisting of mono-, di- and triglycerides or mixtures thereof and nickel chelating lipids, and the liquid lipids are surfactants.

7. The formulation of claim 1 , wherein the cell penetrating peptide is selected from the group consisting of a transactivating transcriptional activator protein (TAT), YARA, penetratin, and polyarginine (R n ) where Rn is Arg 8 , Arg 11 or Arg 15 .

8. The formulation of claim 7 , wherein the TAT is Gly-Tyr-Arg-Lys -Lys-Arg-Arg-Gln-Arg-Arg-Arg-His-His-His-His-His-His.

9. The formulation of claim 1 , wherein the cell penetrating peptides are attached to the nanoparticles with DOGS-NTA-Ni chelating lipid.

10. The formulation of claim 1 , wherein the cell penetrating peptide is a polyarginine (R n ) where n is 8, 11, or 15.

Assignments (2)
CONFIRMATORY LICENSE Recorded May 20, 2015
From: FLORIDA AGRICULTURAL AND MECHANICAL UNIV
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 035742/0464 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 21, 2014
From: PATLOLLA, RAM
To: FLORIDA AGRICULTURAL AND MECHANICAL UNIVERSITY
Reel/Frame 032499/0353 →
Continuity (1)
Related Publication 20120195957A1 · Aug 2, 2012